Evonik Shifts to Flexible Dividend Policy Amid Strategic Overhaul

Evonik presents a flexible dividend policy linked to earnings and an 11% ROCE target. The strategy aims to fund growth in high-margin segments while addressing investor concerns.

The specialty chemicals group Evonik is actively engaging with its institutional shareholder base, conducting a series of international roadshows in cities including London, Milan, and Montreal. These meetings are focused on presenting the company's revised strategic direction, with a significant portion dedicated to addressing a key investor concern: the adoption of a more adaptable dividend framework.

Financial Targets and Capital Allocation

Alongside its strategic update, Evonik has reaffirmed its operational guidance to market analysts. For the ongoing 2026 fiscal year, the company anticipates its adjusted EBITDA will land between €1.7 billion and €2.0 billion, a range consistent with the prior year's performance. Looking further ahead, management has set an ambitious long-term goal of achieving a return on capital employed (ROCE) of 11%. This represents a substantial increase from the 6.1% ROCE reported for 2025.

The new dividend policy is central to funding this transformation. For the concluded 2025 financial year, the board has already proposed a reduced payout of €1.00 per share. Beginning in 2026, a new system will take effect, directly linking the annual distribution to the company's adjusted net income. Evonik is targeting a payout ratio between 40% and 60%, a range designed to provide greater financial flexibility. Capital retained through this model will be primarily allocated to debt reduction and investing in high-margin specialty chemical segments, such as colloidal silica.

Market Sentiment and Upcoming Catalysts

The market's reception to Evonik's restructuring efforts has been cautious so far. The company's shares closed at €14.35 on Monday, reflecting a decline of approximately 31% over a twelve-month period. While a 14-day Relative Strength Index (RSI) reading of 28.9 suggests the stock may be in oversold territory in the short term, it also underscores the persistent weakness within a sector facing broader economic uncertainties.

Investors will have several opportunities to assess the company's operational progress in the coming months. Following additional investor meetings scheduled for late March, Evonik will publish its first-quarter results on May 8. The formal shareholder vote on the proposed reduced dividend for 2025 is then scheduled for the Annual General Meeting on June 3, 2026.